SLC22A6 and chronic kidney disease: Hsueh et al. reviewed clinical studies regarding the inhibition of OAT1 and OAT3 in CKD patients, and their data suggest that uremic solutes contribute to the decline in renal drug clearance in CKD patients by inhibition of OAT1 and OAT3 [147].